<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04701151</url>
  </required_header>
  <id_info>
    <org_study_id>2020-003112-27</org_study_id>
    <nct_id>NCT04701151</nct_id>
  </id_info>
  <brief_title>NORTH-REG Dwell-Time Study</brief_title>
  <official_title>Nordic Urothelial Cancer Research Group Study on Reduced BCG Dwell-Time in High Risk NMIBC</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Jørgen Bjerggaard Jensen</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Aarhus University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Herlev Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Odense University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Aalborg University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Regional Hospital West Jutland</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Rigshospitalet, Denmark</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Zealand University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Landspitali University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Sahlgrenska University Hospital, Sweden</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Region Örebro County</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>The Hospital of Vestfold</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Aarhus University Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Previous studies show that the majority NMIBC patients experience side effects to BCG and&#xD;
      therefore terminate the instillations before completing all planned instillations. This will&#xD;
      increase their risk of recurrence and potential cystectomy. The purpose of this study is to&#xD;
      investigate if NMIBC patients who experience severe side effects to BCG instillations will&#xD;
      experience fewer or less severe side effects if reducing dwell-time of BCG instillations.&#xD;
&#xD;
      The study will include patients from Denmark, Iceland, Norway and Sweden.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Approximately 8,000 patients are diagnosed with bladder cancer (BC) in the Nordic countries&#xD;
      every year. The majority of BC patients are diagnosed with non-muscle invasive bladder cancer&#xD;
      (NMIBC). The majority of NMIBC are treated with Bacillus Calmette-Guérin vaccine (BCG) as&#xD;
      adjuvant treatment but for carcinoma in situ it is the primary treatment. BCG is known to&#xD;
      give a lot of side effects both local and systemic, the severity of these can lead to&#xD;
      premature termination of the treatment.&#xD;
&#xD;
      The object of this PhD project is to investigate if reduced dwell time, the time the BCG is&#xD;
      in the bladder, will decrease the severity of side effects due to BCG instillations.&#xD;
&#xD;
      This will be investigated in a Nordic setting and the project will be done as a two-armed&#xD;
      randomized clinical trial.&#xD;
&#xD;
      By decreasing the severity of side effects, we hypothesize the number of patients completing&#xD;
      all planned instillations will increase and thereby decrease the risk of the BC evolving into&#xD;
      a more aggressive type.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 3, 2021</start_date>
  <completion_date type="Anticipated">November 2023</completion_date>
  <primary_completion_date type="Anticipated">February 2022</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>multi-center, multi-national, two-armed, randomized, open-label, investigator-initiated clinical controlled - phase IV trial.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Completion of instillations</measure>
    <time_frame>5 years</time_frame>
    <description>Number of Study Subjects completing all 6 induction instillations and subsequent maintenance installations for 12 months (6 + 3 x 3)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Recurrence rate</measure>
    <time_frame>5 years</time_frame>
    <description>Recurrence rate within 24 months in Study Subjects with initial complete response</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">314</enrollment>
  <condition>Side Effect of Drug</condition>
  <arm_group>
    <arm_group_label>Intervention</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Study Subjects randomized to the interventional arm will be assigned to BCG induction therapy once-weekly for 6 weeks and subsequent 1 year of maintenance (6+3x3) of which dwell-time during the first of the 6 induction instillations is 2 hours.&#xD;
If side effects are registered before the second and all further instillations, Study Subject in the intervention arm will be reduced in dwell-time according to the grading of side effects as given by the study algorithm.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>The Study Subjects will be treated according to guidelines with BCG instillation therapy once weekly for 6 weeks and subsequent 1 year of maintenance therapy (6+3x3) with 2 hours of dwelltime.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bacillus Calmette Guerin</intervention_name>
    <description>The same dose of the drug will be given in both arms but the dwell-time will be adjusted for the subjects in the intervention arm according to the grading of side effects given by the study algorithm.</description>
    <arm_group_label>Control</arm_group_label>
    <arm_group_label>Intervention</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  ≥18 years of age at the time of signing the Informed Consent Form&#xD;
&#xD;
          -  Signed Informed Consent Form&#xD;
&#xD;
          -  Patients with NMIBC where BCG therapy including maintenance for 1 year is planned for&#xD;
             one of the following histopathological findings:&#xD;
&#xD;
          -  Ta high grade without CIS&#xD;
&#xD;
          -  CIS with or without previous or concomitant Ta tumors&#xD;
&#xD;
          -  T1 with or without CIS&#xD;
&#xD;
          -  Is, according to the Investigator's judgement, able to comply with the trial protocol&#xD;
&#xD;
          -  Ability to understand the Patient Information Sheet orally and in writing&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Previous BCG instillations&#xD;
&#xD;
          -  T1 tumors where re-resection had not been performed&#xD;
&#xD;
          -  TUR-B, bladder biopsy or traumatic catheterization within 2 weeks.&#xD;
&#xD;
          -  Previous or current MIBC&#xD;
&#xD;
          -  Previous or current metastatic urothelial carcinoma&#xD;
&#xD;
          -  Contraindications to BCG&#xD;
&#xD;
          -  Incontinence&#xD;
&#xD;
          -  Need for catheter a demeure at the time of instillation&#xD;
&#xD;
          -  Immune Suppressing medication (cancer therapy e.g cytostatic medicinal products,&#xD;
             radiation, local and systemic steroids like e.g. prednisolone is permitted)&#xD;
&#xD;
          -  Reduced immune response (leukaemia, lymphoma)&#xD;
&#xD;
          -  Known allergy or sensitivity to BCG&#xD;
&#xD;
          -  HIV infection&#xD;
&#xD;
          -  Signs of active tuberculosis&#xD;
&#xD;
          -  Previously radiation therapy of the bladder&#xD;
&#xD;
          -  Known with another cancer diagnosis, except prostate cancer&#xD;
&#xD;
          -  Current urinary tract infection&#xD;
&#xD;
          -  Patient with visible hematuria&#xD;
&#xD;
          -  Current alcohol and/or drug abuse&#xD;
&#xD;
          -  Has a mental or legal incapacitation or another condition which impair the subject's&#xD;
             ability to participate&#xD;
&#xD;
          -  Has participated in another interventional clinical study and treatment with another&#xD;
             investigational product 30 days prior to randomization&#xD;
&#xD;
          -  For women study subjects: Pregnancy or breastfeeding&#xD;
&#xD;
          -  For women Study subjects of childbearing potential: unless they are using highly&#xD;
             effective methods of contraception from the first BCG instillations until 14 days&#xD;
             after last dose of BCG treatment, which are defined as total abstinence, female&#xD;
             sterilization, use of oral methods of contraception or placement of an intrauterine&#xD;
             contraception devices.&#xD;
&#xD;
          -  For male Study Subjects: unless they are using highly effective methods of&#xD;
             contraception from the first BCG instillation until for 14 days after last dose of BCG&#xD;
             treatment, which is defined as total abstinence or use of condoms.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Jørgen B. Jensen, Professor,DMSc</last_name>
    <phone>+45 78452617</phone>
    <email>Bjerggaard@skejby.rm.dk</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Lene Munk, MD</last_name>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Aarhus University Hospital</name>
      <address>
        <city>Aarhus</city>
        <state>Aarhus N</state>
        <zip>8200</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lene Munk, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Department of Urology, Aalborg University Hospital</name>
      <address>
        <city>Aalborg</city>
        <zip>9100</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Knud Fabrin, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Herlev Hospital</name>
      <address>
        <city>Herlev</city>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Gitte Lam, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Regional Hospital West Jutland</name>
      <address>
        <city>Holstebro</city>
        <zip>7500</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Erik Hansen, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Department of Urology, Rigshospitalet</name>
      <address>
        <city>København</city>
        <zip>2100</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Ulla Nordström Joensen, MD, PhD Assoc. Professor</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Odense University Hospital</name>
      <address>
        <city>Odense</city>
        <zip>5000</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Lasse Bro, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Zealand University Hospital</name>
      <address>
        <city>Roskilde</city>
        <zip>4000</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Juan Luis Vásquez, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Landspitali University Hospital</name>
      <address>
        <city>Reykjavík</city>
        <zip>101</zip>
        <country>Iceland</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Sigurdur Gudjonsson</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Vestfold Hospital</name>
      <address>
        <city>Tønsberg</city>
        <zip>NO-3116</zip>
        <country>Norway</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Erik Skaaheim Haug</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>PO Sahlgrenska Universitetssjukhuset</name>
      <address>
        <city>Göteborg</city>
        <zip>sw 413 45</zip>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Viveka Ströck, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Örebro University Hospital</name>
      <address>
        <city>Örebro</city>
        <zip>701 85</zip>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Tomas Jerlsström</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Denmark</country>
    <country>Iceland</country>
    <country>Norway</country>
    <country>Sweden</country>
  </location_countries>
  <verification_date>February 2021</verification_date>
  <study_first_submitted>January 6, 2021</study_first_submitted>
  <study_first_submitted_qc>January 6, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">January 8, 2021</study_first_posted>
  <last_update_submitted>February 3, 2021</last_update_submitted>
  <last_update_submitted_qc>February 3, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">February 5, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Aarhus University Hospital</investigator_affiliation>
    <investigator_full_name>Jørgen Bjerggaard Jensen</investigator_full_name>
    <investigator_title>Professor, Consultant, MD, DMSc Department of Clinical Medicine, Aarhus University</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Drug-Related Side Effects and Adverse Reactions</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>BCG Vaccine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

